Effect of pentoxifylline on the evolution of diabetic nephropathy;Efecto de la pentoxifilina sobre la evolución de la nefropatía diabética

Medicina Clinica

Volumn 132, Issue 20, 2009, Pages 772-778

  Leyva Jiménez, Rafael ^a   Rodríguez Orozco, Alaín R ^b   Ortega Pierres, Luz Elena ^b   Ramírez Enríquez, Jesús ^a   Gómez García, Anel ^a,d   Alvarez Aguilar, Cleto ^a,c  

^a Instituto Mexicano de Seguro Social (IMSS)   (Mexico)

^b UNIVERSIDAD MICHOACANA DE SAN NICOLÁS DE HIDALGO   (Mexico)

^c HOSPITAL DE ESPECIALIDADES   (Mexico)

^d Laboratorio de Neurofisiología Experimental   (Mexico)

Author keywords

Diabetic nephropathy; Inflammation; Pentoxifylline; Pro inflammatory cytokines; Type 2 diabetes

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CYTOKINE; INTERLEUKIN 6; LEPTIN; PENTOXIFYLLINE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INFLAMMATION; KIDNEY INJURY; MALE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; RENAL PROTECTION; URINARY EXCRETION;

EID: 67349093307     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2008.05.024     Document Type: Article

References (42)

1. W.F. Keane, B.M. Brenner, D. De Zeeuw, J.P. Grunfeld, J. Mcgill, and W.E. Match The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy. The RENAAL Study Kidney Int 63 2003 1499 1507 (Pubitemid 36350016)
2. F.P. Schena, G. Grandaliano, V. Montinaro, E. Ranieri, R. Monno, and L. Gesualdo Cytokine, chemokine and growth factor expression in the pathogenesis of progressive renal damage Nephrology 3 1997 663 669
3. R.E. Gilbert, H. Krumt, J. Wilkinson-Berka, and D.J. Kelly The renin-angiotensin system and the long-term complications of diabetes: Pathophysiological and therapeutic considerations Diabetic Medicine 20 2003 607 621 (Pubitemid 36966554)
4. M. Rodríguez-Morán, and F. Guerrero-Romero Increased levels of C-reactive protein in non-controlled type ii diabetic subjects J Diabetes Complications 19 1999 211 215
5. J. Pickup, G. Chusney, S. Thomas, and D. Burt Plasma interleukin-6, tumor necrosis factor α and blood cytokine production in type 2 diabetes Life Sci 67 2000 291 300 (Pubitemid 30413937)
6. H.J. Anders, V. Vielhauer, and D. Schlondorff Chemokines and chemokine receptors are involved in the resolution or progression of renal disease Kidney Int 63 2003 401 415 (Pubitemid 36126787)
7. J.A. Joles, and H.A. Koomans Causes and consequences of increased sympathetic activity in renal disease Hypertension 43 2004 699 706 (Pubitemid 38405571)
8. I.H. Klein, G. Ligtenberg, P.L. Ocy, H.A. Koomans, and P.J. Blankestijn Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension J Am Soc Nephrol 12 2001 2427 2433 (Pubitemid 33021120)
9. D.M. Renn, L.C. Jordan, E.W. Kelso, J.E. Davenport, and R.B. Harris Effects of central or peripheral leptin administration on norepinephrine turnover in defined fat depots Am J Physiol Regul Integr Comp Physiol 291 2006 R1613 R1621
10. K. Sharma, R.V. Considine, B. Michael, S.R. Dunn, L.S. Weisberg, and B.R.C. Kurnik Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients Kidney Int 51 1997 1980 1985 (Pubitemid 27252771)
11. E.J. Lewis, L.G. Hunaixker, R.P. Brain, and R.D. Pohde The effect of angiotensin converting enzyme inhibition in diabetic nephropathy N Eng J Med 323 1993 1456 1462 (Pubitemid 23335891)
12. E.J. Lewis, L.G. Hunsicker, W.R. Clarke, T. Berl, M.A. Pohl, and J.B. Lewis Renoprotective effect or the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Eng J Med 345 2001 851 860
13. Y.M. Chen, Y.Y. Ng, S.L. Lin, W.C. Chiang, H.Y. Lan, and T.J. Tsai Pentoxifylline suppresses renal tumour necrosis factor-α and ameliorates experimental crescentic glomerulonephritis in rats Nephrol Dial Transplant 19 2004 1106 1115 (Pubitemid 38628128)
14. F. Guerrero-Romero, M. Rodríguez-Moran, J.R. Paniagua-Sierra, G. García-Bulnes, M. Salas-Ramírez, and D. Amato Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients Clin Nephrol 43 1995 116 121
15. A. Ward, and S.P. Clissold Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy Drugs 34 1987 50 97 (Pubitemid 17092322)
16. H.C. Heystek, A.C. Thierry, P. Soulard, and C. Moulon Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity Int Immunol 15 2003 827 835 (Pubitemid 36827071)
17. L. Jeyaseelan, and P.S.S. Rao Methods of determining sample sizes in clinical trials Indian Pediatrics 26 1989 115 121
18. American Diabetes Association Diagnosis and classification of diabetes mellitus Diabetes Care 28 Suppl 1 2005 37 42
19. American Diabetes Association Nephropathy in diabetes Diabetes Care 27 2004 S79 S83
20. D.W. Coccroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephrol 16 1976 31 41
21. J.R. Leyva, A.C. Álvarez, and M.M.G. López Función renal en diabéticos tipo 2, determinada por fórmula de Cockcroft-Gault y depuración de creatinina Rev Med IMSS 42 2004 5 10
22. J.F. Navarro, C. Mora, A. Rivero, E. Gallego, J. Chahin, and M. Macia Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: Effects of pentoxifylline administration Am J Kidney Dis 33 1999 458 463 (Pubitemid 29107022)
23. J.F. Navarro, F.J. Milena, C. Mora, C. León, and J. García Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: Effect of angiotensin-converting enzyme inhibition and pentoxifylline administration Am J Nephrol 26 2006 562 570 (Pubitemid 46143878)
24. G. Galindo-Rodríguez, R. Bustamante, G. Esquivel-Nava, D. Salazar-Exaire, J. Vela-Ojeda, and M. Vadillo-Buenfil Pentoxifylline in the treatment of refractory nephrotic syndrome secondary to lupus nephritis J Rheumatol 30 2003 2382 2384 (Pubitemid 37413897)
25. D. Ducloux, C. Bresson-Vautrin, and J.M. Chalopin Use of pentoxifylline in membranous nephropathy Lancet 357 2001 1672 1673 (Pubitemid 32568243)
26. M. Saraheimo, A.M. Teppo, C. Forsblom, J. Fagerudd, and P.H. Groop Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patient Diabetologia 46 2003 1402 1407 (Pubitemid 37297211)
27. J.C. Pickup, M.B. Mattock, G.D. Chusney, and D. Burt NIDDM as a disease of the innate immune system: Association of the acute-phase reactants and interleukin-6 with metabolic syndrome X Diabetologia 40 1997 1286 1292 (Pubitemid 27469668)
28. J.C. Pickup, M.B. Mattock, G.D. Chusney, and D. Burt NIDDM as a disease of the innate immune system: Association of the acute-phase reactants and interleukin-6 with metabolic syndrome X Diabetología 40 1997 1286 1292 (Pubitemid 27469668)
29. E.M. Stuvling, S.J.L. Bakker, H.L. Hillege, J.G.M. Burgerhof, P.E. De Jong, and R.O.B. Gans C-reactive protein modifies the relationship between blood pressure and microalbuminuria Hypertension 43 2004 791 796 (Pubitemid 38405589)
30. R.M. Strieter, D.G. Remick, P.A. Ward, R.N. Spengler, J.P. Lynch, and J. Larrick Cellular and molecular regulation of TNF-alpha production by pentoxifylline Biochem Biophys Res Commun 155 1988 1230 1236 (Pubitemid 18235327)
31. J. Navarro Nefropatía diabética: ¿Una cuestión de inflamación? Hipótesis del daño renal inflamatorio en la diabetes mellitus tipo 2 Nefrología XXIII 2003 381 389 (Pubitemid 39233228)
32. R.J. Johnson, K.L. Gordon, S. Suga, A.M. Duijvestijn, K. Griffin, and A. Bidani Renal injury and salt-sensitive hypertension after exposure to catecholamines Hypertension 34 1999 151 159 (Pubitemid 29325734)
33. C. Erami, H. Zhang, J.G. Ho, D.M. French, and J.E. Faber Alpha(1)-adrenoceptor stimulation directly induces growth of vascular wall in vivo Am J Physiol Heart Circ Physiol 283 2002 H1577 H1587
34. H. Zhang, and J.E. Faber Trophic effect of norepinephrine on arterial intima-media and adventitia is augmented by injury and mediated by different alpha1-adrenoceptor subtypes Circ Res 89 2001 815 822 (Pubitemid 34633853)
35. B.F. Schultes, W. Kern, J. Beyer, T. Forst, A. Pfützner, and A. Peters Elevated serum leptin concentrations in type 2 diabetic patients with microalbuminuria and macroalbuminuria Metabolism 48 1999 1290 1293 (Pubitemid 29496078)
36. G.M. Lord Leptin as a proinflammatory cytokine Contrib Nephrol 151 2006 151 164
37. P. Pecois-Filho, L. Nordfors, O. Heimburger, B. Lindholm, B. Anderstam, and A. Marhlewska Soluble leptin receptors and serum leptin in end-stage renal disease: Relationship with inflammation and body composition Eur J Clin Ivest 32 2002 811 817 (Pubitemid 35356932)
38. M.S. Zumbach, M.W. Bochme, P. Wahl, W. Stemmel, R. Ziegler, and P.P. Nawroth Tumor necrosis factor increases serum leptin levels in humans J Clin Endocrinol Metab 82 1997 4080 4082 (Pubitemid 27525517)
39. S.L. Lin, Y.M. Chen, W.C. Chiang, T.J. Tsai, and W.Y. Chen Pentoxifylline: A potential therapy for chronic kidney disease Nephrology 9 2004 198 204
40. C. Álvarez-Aguilar, L.I. Mondragón-Jiménez, J. Ramírez-Enríquez, A. Gómez-García, R. Paniagua-Sierra, and D. Amato Hiperleptinemia como factor de riesgo en hipertensión arterial asociada a obesidad Med Clin (Barc) 123 2004 766 769 (Pubitemid 40128790)
41. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure 2003 The National High Blood Pressure Education Program Committee JAMA 289 2003 2560 2572
42. J. Biarnéz, Ll. Masana, C. Morales, X. Pintó, and W. Ricart Factores que influyen en la aparición de la nefropatía diabética incipiente: estudio ESODIAH Med Clin (Barc) 125 2005 401 404 (Pubitemid 41565782)